Journal
ATHEROSCLEROSIS
Volume 199, Issue 2, Pages 237-247Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2008.03.006
Keywords
endothelin-1; vascular smooth muscle cell; cell signalling; atherosclerosis
Funding
- National Health & Medical Research Council of Australia
- National Heart Foundation of Australia and the Diabetes Australia Research Trust
- National Health & Medical Research Council of Australia Scholarship and Monash University and the Baker Heart Research Institute
- Eli Lilly Endocrinology Research Awards and GlaxoSmithKline Kline student Support awards
Ask authors/readers for more resources
Atherosclerosis is the primary ischaemic Vascular condition Underlying a majority of cardiovascular disease related deaths. Endothelin-1 is a vasoactive peptide agent upregulated in atherosclerosis and in conjunction with its G protein-coupled receptors exerts diverse actions oil all cells of the vasculature in particular vascular smooth muscle cells (VSMC). The effects of endothelin-1 include cell proliferation, migration and contraction, and the induction of extracellular matrix components and growth factors. VSMC as the major component of the neointima in atherosclerotic plaques accordingly play a key role in atherogenesis. In this review we examine classic and novel signalling pathways activated by endothelin-1 ill VSMC (including phospholipase C, adenylate cyclase, Rho kinase, transactivation of receptor tyrosine kinases, mitogen activated protein kinase cascades and beta-arrestin) and their likely impact on the development and progression of atherosclerosis. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available